Conradsson David, Paquette Caroline, Lökk Johan, Franzén Erika
Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Alfred Nobels Alle 23, 141 83 Huddinge, Sweden; Functional Area Occupational Therapy & Physiotherapy, Allied Health Professionals Function, Karolinska University Hospital, Stockholm, Sweden.
Department of Kinesiology and Physical Education, McGill University, and Interdisciplinary Research Center in Rehabilitation (CRIR), 475 Pine Avenue West, Montreal, Quebec H2W 1S4, Canada.
Neuroscience. 2017 Jan 26;341:18-26. doi: 10.1016/j.neuroscience.2016.11.016. Epub 2016 Nov 17.
Although dopaminergic medication improves functional mobility in individuals with Parkinson's disease (PD), its effects on walking turns are uncertain. Our goals was to determine whether dopaminergic medication improves preplanned and unplanned walking turns in individuals with PD, compared to healthy controls. Nineteen older adults with mild-to-moderate PD and 17 healthy controls performed one of the following three tasks, presented randomly: walking straight, or walking and turning 180° to the right or left. The walking direction was visually cued before starting to walk (preplanned) or after (unplanned, i.e., 0.6m before reaching the turning point). Subjects with PD were assessed off dopaminergic medication (OFF) and on dopaminergic medication (ON) medication. Turning strategy (step and spin turns), turning performance (turning distance and body rotation) and walking pattern were analyzed for three turning steps. Irrespective of medication state and turning condition, step and spin turns followed a nearly 50:50 distribution. After intake of dopaminergic medication, subjects with PD increased their turning distance but not the amount of body rotation or their walking pattern. Compared to controls, turning impairments in subjects with PD remained while ON medication and problems regulating step width were the most prominent features of their walking pattern. Specifically, subjects with PD turned with narrower cross-over steps, i.e. when the external foot crossed over the line of progression of the internal leg. We conclude that turning impairments remained even after dopaminergic medication and problems modulating step width appears to be a critical feature for turning in PD.
尽管多巴胺能药物可改善帕金森病(PD)患者的功能性活动能力,但其对步行转向的影响尚不确定。我们的目标是确定与健康对照相比,多巴胺能药物是否能改善PD患者的预计划和非计划步行转向。19名轻度至中度PD的老年人和17名健康对照者随机进行以下三项任务之一:直线行走、向右或向左转180°行走。在开始行走前(预计划)或之后(非计划,即在到达转折点前0.6米)通过视觉提示行走方向。对PD患者在停用多巴胺能药物(OFF)和服用多巴胺能药物(ON)时进行评估。分析三个转向步骤的转向策略(步转和自旋转)、转向表现(转向距离和身体旋转)和行走模式。无论药物状态和转向条件如何,步转和自旋转的分布接近50:50。服用多巴胺能药物后,PD患者增加了转向距离,但身体旋转量或行走模式未改变。与对照组相比,PD患者在服用药物时仍存在转向障碍,步幅调节问题是其行走模式最突出的特征。具体而言,PD患者以更窄的交叉步转向,即当外侧脚越过内侧腿的行进线时。我们得出结论,即使在使用多巴胺能药物后,转向障碍仍然存在,步幅调节问题似乎是PD患者转向的关键特征。